Ambrx Biopharma, Inc.
(NASDAQ GS: AMAM)
Rigrodsky Law, P.A. is investigating Ambrx Biopharma, Inc. (“Ambrx”) regarding possible breaches of fiduciary duties and other violations of law related to Ambrx’s agreement to be acquired by Johnson & Johnson. Under the terms of the agreement, Ambrx shareholders will receive $28.00 per share in cash.